- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibitors of BRAF dimers using an allosteric site
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-01
DOI
10.1038/s41467-020-18123-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quest for Clinically Effective RAF Dimer Inhibitors
- (2020) Jenny Y. Xue et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
- (2019) Ryan J. Sullivan et al. MOLECULAR CANCER THERAPEUTICS
- Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
- (2019) Thomas Botton et al. Cell Reports
- Current Insights of BRAF Inhibitors in Cancer
- (2018) Bogos Agianian et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
- (2018) Zhan Yao et al. NATURE MEDICINE
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Polypharmacology-based ceritinib repurposing using integrated functional proteomics
- (2017) Brent M Kuenzi et al. Nature Chemical Biology
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
- (2016) Zoi Karoulia et al. CANCER CELL
- Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases
- (2016) Krisna C. Duong-Ly et al. Cell Reports
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
- (2015) Tea Pemovska et al. NATURE
- Regulation of RAF protein kinases in ERK signalling
- (2015) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
- (2014) Jacob R. Haling et al. CANCER CELL
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
- (2014) Neroshan Thevakumaran et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
- (2013) Oscar P. J. van Linden et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives
- (2013) Masanori Okaniwa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Collaboration gets the most out of software
- (2013) Andrew Morin et al. eLife
- Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT and against FGFR1-derived fusion kinases
- (2012) E Lierman et al. LEUKEMIA
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Evolution of the eukaryotic protein kinases as dynamic molecular switches
- (2012) S. S. Taylor et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- iMOSFLM: a new graphical interface for diffraction-image processing withMOSFLM
- (2011) T. Geoff G. Battye et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Overview of theCCP4 suite and current developments
- (2011) Martyn D. Winn et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
- (2011) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started